-
Story
The Day AI Made Me Rethink What Science Could Do -
Story
American Chemical Society honors Novartis researchers -
Story
How Novartis R&D is advancing the next breakthrough innovations -
Press Release
Scemblix® continued to show superior efficacy and favorable safety and tolerability profile at week 144 in newly diagnosed CML
-
Press Release
Pluvicto™ demonstrated consistent efficacy across key patient subgroups in metastatic hormone-sensitive prostate cancer
-
Story
Pushing the prostate cancer treatment frontier: Radioligand therapy and beyond -
Press Release
New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer
-
Story
Full Circle: A Story of Growth, Purpose and Coming Home to Novartis -
Story
Bringing proteins together to take cancer apart -
Story
Breaking ground in Global Health -
Press Release
New real‑world data reinforce earlier use of Pluvicto™ before chemotherapy in metastatic castration-resistant prostate cancer
-
Story
What's next in Neuroscience drug discovery